Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMCLHZ5)

Drug Name
splitomicin Drug Info
Synonyms
splitomicin; 5690-03-9; 1,2-Dihydro-3H-naphtho[2,1-b]pyran-3-one; 1,2-dihydro-3h-benzo[f]chromen-3-one; 1H-benzo[f]chromen-3(2H)-one; CHEMBL86537; CHEBI:75272; 1,2-dihydrobenzo[f]chromen-3-one; 1H,2H,3H-naphtho[2,1-b]pyran-3-one; Splitomycin; Bio2_000878; Tocris-1542; AC1L1JZ6; AC1Q6ML4; KBioGR_000456; BSPBio_001116; KBioSS_000456; GTPL8101; SCHEMBL2544804; ZINC27374; KBio3_000852; KBio2_003024; BDBM29590; KBio3_000851; KBio2_005592; KBio2_000456; MolPort-003-959-546; ISFPDBUKMJDAJH-UHFFFAOYSA-N; HMS1362H17; HMS1990H17; Bio2_000398
Cross-matching ID
PubChem CID
5269
ChEBI ID
CHEMBL86537
CAS Number
CAS 5690-03-9
TTD Drug ID
D09SUO

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.19 0.00e+0 34/36 (94.44%) POLE2;MCM4;POLD3;...
Mineral absorption 2.15 0.00e+0 48/60 (80%) MT1E;MT1X;MT1H;...
Fanconi anemia pathway 2.00 8.66e-3 36/54 (66.67%) BRCA1;CENPX;BRCA2;...
Glycine, serine and threonine metabolism -1.67 4.86e-2 31/40 (77.5%) BHMT;GNMT;SHMT2;...
Phagosome -1.69 4.20e-2 118/152 (77.63%) TUBB;HLA-F;CTSL;...
T cell receptor signaling pathway -1.69 4.27e-2 93/104 (89.42%) RELA;MAPK3;CD3G;...
Th1 and Th2 cell differentiation -1.71 3.72e-2 80/92 (86.96%) JAK2;MAF;PRKCQ;...
Toll-like receptor signaling pathway -1.72 3.66e-2 94/104 (90.38%) CXCL9;MAPK13;TLR7;...
Steroid biosynthesis -1.74 3.70e-2 19/20 (95%) NSDHL;CYP51A1;HSD17B7;...
Systemic lupus erythematosus -1.74 3.99e-2 45/135 (33.33%) IFNG;C5;HLA-DQA1;...
Tryptophan metabolism -1.78 3.00e-2 35/42 (83.33%) GCDH;ALDH7A1;AOC1;...
AGE-RAGE signaling pathway in diabetic complications -1.79 2.96e-2 97/100 (97%) PLCB1;STAT3;MAPK11;...
Antigen processing and presentation -1.82 1.63e-2 60/78 (76.92%) HSPA4;HSPA8;B2M;...
Graft-versus-host disease -1.84 1.52e-2 32/42 (76.19%) HLA-E;CD80;HLA-C;...
Leishmaniasis -1.85 1.63e-2 67/77 (87.01%) CR1;IRAK4;JAK2;...
Pertussis -1.87 1.45e-2 64/76 (84.21%) MAPK11;IL23A;RHOA;...
Staphylococcus aureus infection -1.96 5.45e-3 72/95 (75.79%) PTAFR;CAMP;CFB;...
Rheumatoid arthritis -2.03 1.09e-2 78/93 (83.87%) ICAM1;CTSL;CTLA4;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 25uM 6H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 3.33uM 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H